EpiBiologics is focused on advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins, leveraging their EpiTAC platform to create tissue-selective therapies for cancer and autoimmune disorders
EpiBiologics is focused on advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins, leveraging their EpiTAC platform to create tissue-selective therapies for cancer and autoimmune disorders.
EpiBiologics is focused on advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins, leveraging their EpiTAC platform to create tissue-selective therapies for cancer and autoimmune disorders
EpiBiologics is focused on advancing bispecific antibodies designed to selectively degrade disease-causing extracellular proteins, leveraging their EpiTAC platform to create tissue-selective therapies for cancer and autoimmune disorders.